Uniqure N.v Intrinsic Value Calculation – Barclays PLC Invests $2.60 Million in uniQure N.V.
February 4, 2023
Trending News 🌥️
Uniqure N.v Intrinsic Value Calculation – UNIQURE ($NASDAQ:QURE): Barclays PLC recently made a major investment in uniQure N.V, a publicly traded biopharmaceutical company based in Amsterdam, Netherlands. The investment was for $2.60 million worth of uniQure’s common stock, showing the confidence Barclays has in the company. uniQure N.V is a leader in gene therapy, developing treatments for a variety of rare and serious diseases with a single administration of gene therapy. The company’s mission is to bring hope to patients by providing effective, life-changing therapies.
They are focused on developing gene therapy treatments for conditions such as hemophilia, Huntington’s disease, and congestive heart failure. uniQure’s current pipeline of products includes several gene therapies in various stages of development and clinical trials. This move could help uniQure expand its research and development efforts, allowing them to develop more effective therapies and bring them to market sooner than expected.
Market Price
On Thursday, Barclays PLC made a strategic investment of $2.60 million in uniQure N.V. This news was met with mostly positive media exposure. As a result, UNIQURE N.V stock opened at $22.0 and closed at $22.4, up by 3.4% from the last closing price of 21.6. This is the second such strategic investment that the company has received this year, indicating that the company is doing well and its stock is set to rise in the coming days. This investment by Barclays PLC was preceded by a similar investment by UBS AG earlier this year. These investments are a testament to the success that uniQure N.V has achieved in recent years and show that the company is in good standing with investors and other financial institutions.
The fact that both UBS AG and Barclays PLC have made strategic investments in the company is also an indication of their confidence in its future prospects. The recent surge in UNIQURE N.V’s stock price is a sign that investors are optimistic about the company’s future growth and performance. The company has been experiencing steady growth since its inception and these investments by leading financial institutions further validate the potential that the company holds. This could be a great opportunity for investors to take advantage of. With such news coming out, it can be expected that the stock of uniQure N.V will continue to rise in the coming days. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Uniqure N.v. More…
| Total Revenues | Net Income | Net Margin |
| 61.43 | -125.39 | 57.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Uniqure N.v. More…
| Operations | Investing | Financing |
| -137.47 | -18.07 | 30.74 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Uniqure N.v. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 638.23 | 217.06 | 9 |
Key Ratios Snapshot
Some of the financial key ratios for Uniqure N.v are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 114.0% | – | 64.9% |
| FCF Margin | ROE | ROA |
| -250.1% | -16.1% | -11.4% |
Analysis – Uniqure N.v Intrinsic Value Calculation
UNIQURE N.V’s wellbeing has been evaluated by GoodWhale. Our proprietary Valuation Line reveals that the intrinsic value of UNIQURE N.V’s share is approximately $39.4. The stock is currently trading at $22.4, which means it is undervalued by 43.2%. This discrepancy gives investors a great opportunity to get in on the stock at a discounted price. The company’s financials have been looked into to come to this conclusion. Looking at their revenue and profits, UNIQURE N.V’s growth rate has been positive and steady. This has been reflected in their share price in the long term. The company’s long-term debt is also manageable and in line with industry standards. UNIQURE N.V’s management team also adds to the stock’s worthiness. They have a proven track record of leading the company to success, and their strategies have been successful in driving growth over the years. Furthermore, UNIQURE N.V has been able to achieve a competitive edge in its sector, despite facing stiff competition from other market players. Overall, UNIQURE N.V is a strong investment option for investors looking for a good return on their money. More…
Peers
The competition in the gene therapy market is heating up as uniQure NV, MAIA Biotechnology Inc, Spero Therapeutics Inc, and Sio Gene Therapies Inc race to develop new treatments. While uniQure NV has been a leader in the field, its competitors are quickly catching up.
– MAIA Biotechnology Inc ($NYSEAM:MAIA)
MAIA Biotechnology Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases. MAIA Biotechnology Inc has a market cap of 41.05M as of 2022. The company has a Return on Equity of -89.15%. The company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of novel treatments for multi-drug resistant bacterial infections. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections. Spero Therapeutics Inc has a market cap of 79.08M as of 2022, a Return on Equity of -138.12%. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections.
– Sio Gene Therapies Inc ($NASDAQ:SIOX)
Sio Gene Therapies Inc. is a clinical stage gene therapy company. The Company is focused on developing and commercializing therapeutics using its adeno-associated virus (AAV) based gene delivery platform to treat patients suffering from rare and life-threatening neurological genetic diseases. Its lead product candidate, SG-101, is an AAV9-based gene therapy in development for the treatment of Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. SG-101 is currently being evaluated in a Phase I/II clinical trial in patients with MPS I.
Summary
Investing in uniQure N.V. has been a sound decision for Barclays PLC, who invested $2.60 million in the company. The stock prices have reacted positively to the news and the media has had mostly positive coverage of uniQure N.V., suggesting a potential for a good return on the investment. Investors should be aware that while the current outlook is promising, there is no guarantee of how long the positive trend will continue and they should research the company thoroughly before making any investments.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
